Recently stock market analysts have updated their consensus ratings on shares of IntriCon Corporation (IIN).
Most recent broker ratings
05/06/2015 – IntriCon Corporation was downgraded to “sell” by analysts at Zacks.
08/04/2014 – Dougherty & Co began new coverage on IntriCon Corporation giving the company a “buy” rating. They now have a USD 12 price target on the stock.
IntriCon Corporation has a 50 day moving average of 5.26 and a 200 day moving average of 5.32. The stock’s market capitalization is 40.77M, it has a 52-week low of 4.12 and a 52-week high of 8.65.
The share price of the company (IIN) was up +4.35%, with a high of 6.01 during the day and the volume of IntriCon Corporation shares traded was 4521.
IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market. The Company has facilities in Minnesota, California, Singapore, Indonesia, the United Kingdom and Germany, and operates through its subsidiaries. The Company’s product offering includes a hearing aid discount program for health plans. This program is available around the nation to health insurers, including employer-sponsored, individual and Medicare plans. The Company also has various international value hearing aid (VHA) initiatives.